newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow

  • IGC Pharma announced the beta version of Agentic Harmonization Assistant (AHA), a patent-pending multi-agent platform designed to harmonize fragmented biomedical datasets for AI-ready discovery.
  • Internal testing on an Alzheimer's structured-data workflow with 100 variables reduced harmonization time from 28 hours to 2.5 hours, representing a 90% reduction.
  • AHA utilizes specialized digital agents to profile datasets, propose mappings, generate transformation logic, score confidence, and flag uncertain matches for human review.
  • The platform was developed to resolve operational bottlenecks encountered while building the MINT-AD predictive Alzheimer's risk-stratification engine.
  • IGC plans to demonstrate AHA within the AD Workbench ecosystem at the Alzheimer's Association International Conference (AAIC) 2026 in London from July 12-15.
  • The company is expanding AHA's architecture to support additional modalities including imaging (MRI, PET, CT) & omics (genomics, proteomics).
  • AHA is positioned for broader applications in pharmaceutical, academic, government, & healthcare sectors to accelerate biomarker discovery, cohort generation, & cross-study analysis.
  • Lead therapeutic candidate IGC-AD1 is currently in the Phase 2 CALMA trial for agitation associated with Alzheimer's dementia, having reached 100% of its baseline randomization target.
  • IGC expects to proceed with patient follow-up, database activities, & topline analysis after completing limited over-enrollment for the CALMA trial.
  • Future commercialization strategies for AHA include software licensing, cloud-infrastructure partnerships, & disease-specific deployments.